Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(9):715; doi:10.1093/jnci/djh126
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Campiglio, M.
Right arrow Articles by Ménard, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campiglio, M.
Right arrow Articles by Ménard, S.
Related Collections
Right arrowCorrespondence about this Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor–Negative Mammary Tumors

Manuela Campiglio, Nicola Normanno, Sylvie Ménard

Affiliations of authors: Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan, Italy (MC, SM); Hematology Oncology, INT-Fondazione Pascale, Naples, Italy (NN).

Correspondence to: Sylvie Ménard, PhD, Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy (e-mail: sylvie.menard@istitutotumori.mi.it)

The first 10% of the full text of this article appears below.

In the prevention of breast carcinoma, any new drug capable of inhibiting the onset of breast carcinoma will offer new opportunities to fight this disease. Data from Lu et al. (1) suggested that treatment with ZD1839 (an anti–epidermal growth factor [EGF]-receptor tyrosine-kinase inhibitor) to prevent hormone-independent breast carcinomas might be . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Correspondence about this Article

RESPONSE: Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors
Chunhua Lu, Syed K. Mohsin, Susan Hilsenbeck, Alan Wakeling, and Powel H. Brown
J Natl Cancer Inst 2004 96: 715-716. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
Q. Shen, I. P. Uray, Y. Li, Y. Zhang, J. Hill, X.-C. Xu, M. R. Young, E. J. Gunther, S. G. Hilsenbeck, N. H. Colburn, et al.
Targeting the Activator Protein 1 Transcription Factor for the Prevention of Estrogen Receptor-Negative Mammary Tumors
Cancer Prevention Research, June 1, 2008; 1(1): 45 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Li, Y. Zhang, J. Hill, Q. Shen, H.-T. Kim, X. Xu, S. G. Hilsenbeck, R. P. Bissonnette, W. W. Lamph, and P. H. Brown
The Rexinoid LG100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor Negative Tumors in MMTV-erbB2 Mice
Clin. Cancer Res., October 15, 2007; 13(20): 6224 - 6231.
[Abstract] [Full Text] [PDF]